GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Sera Prognostics Inc (NAS:SERA) » Definitions » PS Ratio

SERA (Sera Prognostics) PS Ratio : 1,043.33 (As of Apr. 03, 2025)


View and export this data going back to 2021. Start your Free Trial

What is Sera Prognostics PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Sera Prognostics's share price is $3.13. Sera Prognostics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 was $0.00. Hence, Sera Prognostics's PS Ratio for today is 1,043.33.

The historical rank and industry rank for Sera Prognostics's PS Ratio or its related term are showing as below:

SERA' s PS Ratio Range Over the Past 10 Years
Min: 129.17   Med: 941.11   Max: 12890
Current: 1043.33

During the past 6 years, Sera Prognostics's highest PS Ratio was 12890.00. The lowest was 129.17. And the median was 941.11.

SERA's PS Ratio is ranked worse than
99.63% of 806 companies
in the Medical Devices & Instruments industry
Industry Median: 3.065 vs SERA: 1043.33

Sera Prognostics's Revenue per Sharefor the three months ended in Dec. 2024 was $0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 was $0.00.

Warning Sign:

Sera Prognostics Inc revenue per share has been in decline over the past 3 years.

During the past 12 months, the average Revenue per Share Growth Rate of Sera Prognostics was -80.00% per year. During the past 3 years, the average Revenue per Share Growth Rate was -12.60% per year. During the past 5 years, the average Revenue per Share Growth Rate was 25.70% per year.

During the past 6 years, Sera Prognostics's highest 3-Year average Revenue per Share Growth Rate was 115.40% per year. The lowest was -12.60% per year. And the median was 65.10% per year.

Back to Basics: PS Ratio


Sera Prognostics PS Ratio Historical Data

The historical data trend for Sera Prognostics's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sera Prognostics PS Ratio Chart

Sera Prognostics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
PS Ratio
Get a 7-Day Free Trial - 2,290.00 140.00 598.00 4,070.00

Sera Prognostics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 598.00 1,516.67 1,973.33 2,600.00 4,070.00

Competitive Comparison of Sera Prognostics's PS Ratio

For the Medical Devices subindustry, Sera Prognostics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sera Prognostics's PS Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Sera Prognostics's PS Ratio distribution charts can be found below:

* The bar in red indicates where Sera Prognostics's PS Ratio falls into.


;
;

Sera Prognostics PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Sera Prognostics's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=3.13/0.003
=1,043.33

Sera Prognostics's Share Price of today is $3.13.
Sera Prognostics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Sera Prognostics  (NAS:SERA) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Sera Prognostics PS Ratio Related Terms

Thank you for viewing the detailed overview of Sera Prognostics's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Sera Prognostics Business Description

Traded in Other Exchanges
N/A
Address
2749 East Parleys Way, Suite 200, Salt Lake City, UT, USA, 84109
Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services.
Executives
Austin Aerts officer: Chief Financial Officer 2479 EAST PARLEYS WAY, SUITE 200, SALT LAKE CITY UT 84109
Robert Gardner Harrison officer: Chief Information Officer 320 WAKARA WAY, SALT LAKE CITY UT 84108
Zhenya Lindgardt director C/O SERA PROGNOSTICS INC, 2749 EAST PARLEYS WAY SUITE 200, SALT LAKE CITY UT 84109
John J. Boniface officer: Chief Scientific Officer C/O SERA PROGNOSTICS, INC., 2749 EAST PARLEYS WAY, SUITE 200, SALT LAKE CITY UT 84109
Mansoor Raza Mirza director C/O KARYOPHARM THERAPEUTICS INC., 2 MERCER ROAD, NATICK MA 01760
Benjamin Jackson officer: General Counsel 320 WAKARA WAY, SALT LAKE CITY UT 84108
Paul Kearney officer: Chief Data Officer 2749 E. PARLEYS WAY, C/O SERA PROGNOSTICS, INC., SALT LAKE CITY UT 84109
Joshua Phillips director C/O SERA PROGNOSTICS, INC., 2749 EAST PARLEYS WAY, SUITE 200, SALT LAKE CITY UT 84109
Jane F Barlow director 6800 BROKEN SOUND PARKWAY NW, 3RD FLOOR, BOCA RATON FL 33487
Michael R Foley officer: Chief Medical Officer C/O SERA PROGNOSTICS INC, 2749 EAST PARLEYS WAY SUITE 200, SALT LAKE CITY UT 04109
Sandra Aj Lawrence director C/O EVERGY, INC., 1200 MAIN STREET, KANSAS CITY MO 64105
Douglas Fisher officer: Chief Business Officer 587 PATROL RD, WOODSIDE CA 94062
Gregory C Critchfield director, officer: Chief Executive Officer 320 WAKARA WAY, SALT LAKE CITY UT 84108
Blue Ox Healthcare Partners Sp, Llc 10 percent owner 135 E. 57TH STREET, 23RD FLOOR, NEW YORK NY 10022
Bxhcp Sp Ii, Llc 10 percent owner 135 E 57TH STREET, 23RD FLOOR, NEW YORK NY 10022